Immunogen (IMGN) 11.70 $IMGN
ImmunoGen, Inc. Pushes Its Pipeline Forward
Brian Orelli, The Motley Fool - Motley Fool - Sat Oct 31, 7:00AM CDT
ImmunoGen reported results from its first fiscal quarter on Tuesday, but there wasn't much to talk about on the financial side. Sales of Kadcyla, the first drug the biotech helped develop, aren't particularly material after ImmunoGen sold the...
JNJ: 101.03 (-0.34), IMGN: 11.70 (+0.16)
Downtrend Call Working As Immunogen Stock Falls 22.2% (IMGN)
Comtex SmarTrend(R) - Wed Oct 28, 10:50AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 22.19% as of today's recent price of $11.12.
IMGN: 11.70 (+0.16)
Shares of IMGN Down 25.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 28, 10:25AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 25.03% as of today's recent price of $10.71.
IMGN: 11.70 (+0.16)
ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 8:40AM CDT
ImmunoGen (IMGN) reported a loss of 39 cents per share in the first quarter fiscal 2016 with total revenues of $14.9 million.
AZN: 31.89 (-0.35), IMGN: 11.70 (+0.16), AMAG: 40.00 (-0.31)
ImmunoGen's (IMGN) Q1FY16 Loss Wider-than-Expected
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 7:34AM CDT
ImmunoGen reported a wider-than-expected loss in the first quarter of fiscal 2016.
IMGN: 11.70 (+0.16)
ImmunoGen Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
Business Wire - Tue Oct 27, 5:30AM CDT
--Level of target expression on patient tumors may have a marked impact on response to mirvetuximab soravtansine, ImmunoGen's novel folate receptor a (FRa)-targeting antibody-drug conjugate (ADC); data to be reported at AACR-NCI-EORTC in November.
IMGN: 11.70 (+0.16)
What Awaits ImmunoGen (IMGN) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Oct 26, 3:01PM CDT
ImmunoGen (IMGN) to report first quarter fiscal 2016 earnings results on Oct 27 before the market opens.
AQXP: 15.29 (+0.73), IMGN: 11.70 (+0.16), BMY: 65.95 (-1.36)
BUYINS.NET: IMGN SqueezeTrigger Price is $11.24. There is $120,266,048 That Short Sellers Still Need To Cover.
M2 - Mon Oct 26, 11:35AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Immunogen Inc (NASDAQ:IMGN) in real time and just received an alert that IMGN is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 10586800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $11.24. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
IMGN: 11.70 (+0.16)
Immunogen Down 25.1% Since SmarTrend Downtrend Call (IMGN)
Comtex SmarTrend(R) - Wed Oct 21, 9:18AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 25.10% as of today's recent price of $10.70.
IMGN: 11.70 (+0.16)
Ergomed Ups the Ante for CEL-SCI
ACCESSWIRE - Wed Oct 21, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Cancer immunotherapy company CEL-SCI Corp. (NYSE MKT: CVM) is thriving. Ergomed, a multinational Contract Research Organization (CRO) with a pristine reputation and the confidence in CEL-SCI's lead drug Multikine to make a huge upfront $10 million investment, recently raised the ante 20% - to $12 million. The deal was done under the same terms first put in place that calls for only a single-digit royalty on potential sales. This clearly shows Ergomed's confidence not only in the likelihood of Multikine being approved, but also in the large revenue potential of the cancer immunotherapy drug.
MNK: 65.67 (-4.32), INO: 6.33 (-0.13), SNTA: 0.67 (+0.01), PCYC: 261.25 (+1.70), ADRO: 27.01 (+0.11), CVM: 0.53 (-0.01), IMGN: 11.70 (+0.16), CLLS: 26.45 (+0.36), AEZS: 0.04 (unch), JUNO: 51.76 (+0.37), BMY: 65.95 (-1.36)
Immunogen Shares Down 28.0% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Tue Oct 13, 4:54PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 28.04% as of today's recent price of $10.28.
IMGN: 11.70 (+0.16)
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2016 Financial Results
Business Wire - Tue Oct 13, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Tuesday, October 27, 2015, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2015. Management also will provide an update on the Company.
IMGN: 11.70 (+0.16)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.93 (-0.14), BIIB: 290.51 (-3.21), NWBO: 4.88 (+0.01), CVM: 0.53 (-0.01), CLDX: 12.06 (-0.22), MACK: 9.34 (-0.22), INO: 6.33 (-0.13), NLNK: 38.27 (+0.89), JUNO: 51.76 (+0.37), GALE: 1.68 (-0.05), IMMU: 2.99 (+0.08), ADXS: 11.09 (-0.66), ADRO: 27.01 (+0.11), IMGN: 11.70 (+0.16), AMGN: 158.18 (-2.40), SPPI: 5.21 (+0.10), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), GSK: 43.06 (+0.27), SRNE: 8.64 (-0.26), ONTY: 2.96 (-0.02), IMUC: 0.39 (-0.01), PGNX: 7.34 (-0.12), ARGS: 5.06 (-0.05), GBIM: 2.48 (-0.09), BLCM: 12.51 (-0.50), SGEN: 41.49 (-0.65), KITE: 68.05 (-0.72), MRK: 54.66 (-0.21)
Immunogen Has Returned 24.8% Since SmarTrend Recommendation (IMGN)
Comtex SmarTrend(R) - Tue Oct 06, 11:29AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 24.82% as of today's recent price of $10.74.
IMGN: 11.70 (+0.16)
Shares of IMGN Down 30.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 29, 9:53AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 30.07% as of today's recent price of $9.99.
IMGN: 11.70 (+0.16)
Stock Updates on Biotechnology -- Celgene, Ariad Pharma, ImmunoGen, BioDelivery Sciences Intl., and Esperion Therapeutics
PR Newswire - Thu Sep 24, 7:06AM CDT
Equity Research Institute has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), ImmunoGen Inc. (NASDAQ: IMGN), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Esperion Therapeutics Inc. (NASDAQ: ESPR). Free research report on Celgene can be accessed at https://www.erionline.net/CELG.pdf On Wednesday, September 23, 2015, the NASDAQ Composite ended at 4,752.74, down 0.08%, the Dow Jones Industrial Average edged 0.31% lower, to finish the day at 16,279.89, and the S&P 500 closed at 1,938.76, down 0.20%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
BDSI: 5.38 (-0.09), ESPR: 24.00 (-0.04), IMGN: 11.70 (+0.16), ARIA: 6.84 (unch), CELG: 122.71 (-2.22), CELGZ: 1.65 (+0.17)
After Yesterday's Decline of 15.90%, Immunogen Offers Investors Better Value
Comtex SmarTrend(R) - Mon Sep 21, 5:28PM CDT
Immunogen (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $12.06 to a high of $14.00. Yesterday, the shares fell 15.9%, which took the trading range below the 3-day low of $13.71 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IMGN: 11.70 (+0.16)
Why ImmunoGen Fell 15% Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Sep 21, 3:50PM CDT
What's happening: After updating investors on its future plans last week and in the wake of an industrywide sell-off, ImmunoGen's shares dropped by over 15% earlier today. Why it's happening: Last week, ImmunoGen's shares rallied up into its...
IMGN: 11.70 (+0.16)
Why ImmunoGen Shares Are Falling Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 18, 1:13PM CDT
What's happening: ImmunoGen hosted an investor presentation this morning that led to the company's shares falling over 10% earlier today. Why it's happening: Since today's drop merely erases gains notched yesterday ahead of the conference,...
IMGN: 11.70 (+0.16)
ImmunoGen, Inc. Pushes Its Pipeline Forward
Brian Orelli, The Motley Fool - Motley Fool - Sat Oct 31, 7:00AM CDT
ImmunoGen reported results from its first fiscal quarter on Tuesday, but there wasn't much to talk about on the financial side. Sales of Kadcyla, the first drug the biotech helped develop, aren't particularly material after ImmunoGen sold the...
JNJ: 101.03 (-0.34), IMGN: 11.70 (+0.16)
Downtrend Call Working As Immunogen Stock Falls 22.2% (IMGN)
Comtex SmarTrend(R) - Wed Oct 28, 10:50AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 22.19% as of today's recent price of $11.12.
IMGN: 11.70 (+0.16)
Shares of IMGN Down 25.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 28, 10:25AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 3 months, Immunogen has returned 25.03% as of today's recent price of $10.71.
IMGN: 11.70 (+0.16)
ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 8:40AM CDT
ImmunoGen (IMGN) reported a loss of 39 cents per share in the first quarter fiscal 2016 with total revenues of $14.9 million.
AZN: 31.89 (-0.35), IMGN: 11.70 (+0.16), AMAG: 40.00 (-0.31)
ImmunoGen's (IMGN) Q1FY16 Loss Wider-than-Expected
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 7:34AM CDT
ImmunoGen reported a wider-than-expected loss in the first quarter of fiscal 2016.
IMGN: 11.70 (+0.16)
ImmunoGen Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
Business Wire - Tue Oct 27, 5:30AM CDT
--Level of target expression on patient tumors may have a marked impact on response to mirvetuximab soravtansine, ImmunoGen's novel folate receptor a (FRa)-targeting antibody-drug conjugate (ADC); data to be reported at AACR-NCI-EORTC in November.
IMGN: 11.70 (+0.16)
What Awaits ImmunoGen (IMGN) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Oct 26, 3:01PM CDT
ImmunoGen (IMGN) to report first quarter fiscal 2016 earnings results on Oct 27 before the market opens.
AQXP: 15.29 (+0.73), IMGN: 11.70 (+0.16), BMY: 65.95 (-1.36)
BUYINS.NET: IMGN SqueezeTrigger Price is $11.24. There is $120,266,048 That Short Sellers Still Need To Cover.
M2 - Mon Oct 26, 11:35AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Immunogen Inc (NASDAQ:IMGN) in real time and just received an alert that IMGN is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 10586800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $11.24. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
IMGN: 11.70 (+0.16)
Immunogen Down 25.1% Since SmarTrend Downtrend Call (IMGN)
Comtex SmarTrend(R) - Wed Oct 21, 9:18AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 25.10% as of today's recent price of $10.70.
IMGN: 11.70 (+0.16)
Ergomed Ups the Ante for CEL-SCI
ACCESSWIRE - Wed Oct 21, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Cancer immunotherapy company CEL-SCI Corp. (NYSE MKT: CVM) is thriving. Ergomed, a multinational Contract Research Organization (CRO) with a pristine reputation and the confidence in CEL-SCI's lead drug Multikine to make a huge upfront $10 million investment, recently raised the ante 20% - to $12 million. The deal was done under the same terms first put in place that calls for only a single-digit royalty on potential sales. This clearly shows Ergomed's confidence not only in the likelihood of Multikine being approved, but also in the large revenue potential of the cancer immunotherapy drug.
MNK: 65.67 (-4.32), INO: 6.33 (-0.13), SNTA: 0.67 (+0.01), PCYC: 261.25 (+1.70), ADRO: 27.01 (+0.11), CVM: 0.53 (-0.01), IMGN: 11.70 (+0.16), CLLS: 26.45 (+0.36), AEZS: 0.04 (unch), JUNO: 51.76 (+0.37), BMY: 65.95 (-1.36)
Immunogen Shares Down 28.0% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Tue Oct 13, 4:54PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 28.04% as of today's recent price of $10.28.
IMGN: 11.70 (+0.16)
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2016 Financial Results
Business Wire - Tue Oct 13, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Tuesday, October 27, 2015, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2015. Management also will provide an update on the Company.
IMGN: 11.70 (+0.16)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.93 (-0.14), BIIB: 290.51 (-3.21), NWBO: 4.88 (+0.01), CVM: 0.53 (-0.01), CLDX: 12.06 (-0.22), MACK: 9.34 (-0.22), INO: 6.33 (-0.13), NLNK: 38.27 (+0.89), JUNO: 51.76 (+0.37), GALE: 1.68 (-0.05), IMMU: 2.99 (+0.08), ADXS: 11.09 (-0.66), ADRO: 27.01 (+0.11), IMGN: 11.70 (+0.16), AMGN: 158.18 (-2.40), SPPI: 5.21 (+0.10), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), GSK: 43.06 (+0.27), SRNE: 8.64 (-0.26), ONTY: 2.96 (-0.02), IMUC: 0.39 (-0.01), PGNX: 7.34 (-0.12), ARGS: 5.06 (-0.05), GBIM: 2.48 (-0.09), BLCM: 12.51 (-0.50), SGEN: 41.49 (-0.65), KITE: 68.05 (-0.72), MRK: 54.66 (-0.21)
Immunogen Has Returned 24.8% Since SmarTrend Recommendation (IMGN)
Comtex SmarTrend(R) - Tue Oct 06, 11:29AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 24.82% as of today's recent price of $10.74.
IMGN: 11.70 (+0.16)
Shares of IMGN Down 30.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 29, 9:53AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on August 13th, 2015 at $14.29. In approximately 2 months, Immunogen has returned 30.07% as of today's recent price of $9.99.
IMGN: 11.70 (+0.16)
Stock Updates on Biotechnology -- Celgene, Ariad Pharma, ImmunoGen, BioDelivery Sciences Intl., and Esperion Therapeutics
PR Newswire - Thu Sep 24, 7:06AM CDT
Equity Research Institute has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), ImmunoGen Inc. (NASDAQ: IMGN), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Esperion Therapeutics Inc. (NASDAQ: ESPR). Free research report on Celgene can be accessed at https://www.erionline.net/CELG.pdf On Wednesday, September 23, 2015, the NASDAQ Composite ended at 4,752.74, down 0.08%, the Dow Jones Industrial Average edged 0.31% lower, to finish the day at 16,279.89, and the S&P 500 closed at 1,938.76, down 0.20%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
BDSI: 5.38 (-0.09), ESPR: 24.00 (-0.04), IMGN: 11.70 (+0.16), ARIA: 6.84 (unch), CELG: 122.71 (-2.22), CELGZ: 1.65 (+0.17)
After Yesterday's Decline of 15.90%, Immunogen Offers Investors Better Value
Comtex SmarTrend(R) - Mon Sep 21, 5:28PM CDT
Immunogen (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $12.06 to a high of $14.00. Yesterday, the shares fell 15.9%, which took the trading range below the 3-day low of $13.71 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IMGN: 11.70 (+0.16)
Why ImmunoGen Fell 15% Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Sep 21, 3:50PM CDT
What's happening: After updating investors on its future plans last week and in the wake of an industrywide sell-off, ImmunoGen's shares dropped by over 15% earlier today. Why it's happening: Last week, ImmunoGen's shares rallied up into its...
IMGN: 11.70 (+0.16)
Why ImmunoGen Shares Are Falling Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 18, 1:13PM CDT
What's happening: ImmunoGen hosted an investor presentation this morning that led to the company's shares falling over 10% earlier today. Why it's happening: Since today's drop merely erases gains notched yesterday ahead of the conference,...
IMGN: 11.70 (+0.16)
